Rituximab in primary membranous nephropathy: First-line therapy, why not?

Nephron - Clinical Practice

Volumn 128, Issue , 2014, Pages 261-269

  Cravedi, Paolo ^a   Remuzzi, Giuseppe ^b,c   Ruggenenti, Piero ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

Author keywords

Membranous nephropathy; Nephrotic syndrome; Proteinuria; Remission; Rituximab

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RITUXIMAB; GLUCOCORTICOID; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADULT; CASE REPORT; CONSERVATIVE TREATMENT; DRUG DOSE TITRATION; DRUG SAFETY; HEMATURIA; HUMAN; HYPERGLYCEMIA; INFECTION; KIDNEY BIOPSY; LEUKOPENIA; LIVER TOXICITY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; MIDDLE AGED; MONOTHERAPY; PRIMARY MEMBRANOUS NEPHROPATHY; PRIORITY JOURNAL; REVIEW; SODIUM RESTRICTION; THROMBOCYTOPENIA; THROMBOSIS; GLOMERULONEPHRITIS, MEMBRANOUS; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; GLOMERULONEPHRITIS, MEMBRANOUS; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; RITUXIMAB;

EID: 84922934981     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000368589     Document Type: Review

References (61)

1. Debiec H, Guigonis V, Mougenot B, Decob-ert F, Haymann JP, Bensman A, et al: Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002; 346:2053-2060.
2. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, et al: Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329:85-89.
3. Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G: Immunosuppres-sive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 2004; 44:385-401.
4. Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, et al: Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheuma-tol 2008; 35:100-105.
5. Chen Y, Schieppati A, Cai G, Chen X, Zamo-ra J, Giuliano GA, et al: Immunosuppression for membranous nephropathy: a systematic review and meta-Analysis of 36 clinical trials. Clin J Am Soc Nephrol 2013; 8:787-796.
6. Braun N, Erley C, Benda N, Zauner I, Kanis R, Grupp C, et al: Therapy of membranous glomerulonephritis with nephrotic syndrome. 5 years follow-up of a prospective, randomised multi-centre study. Nephrol Dial Transplant 1995; 10:967.
7. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, et al: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007; 18:1899-1904.
8. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, et al: A 10-year follow-up of a randomized study with methyl-prednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48:1600-1604.
9. Kosmadakis G, Filiopoulos V, Smirloglou D, Skarlas P, Georgoulias C, Michail S: Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy. Renal Fail 2010; 32:566-571.
10. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, et al: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9:444-450.
11. Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, et al: Immu-nosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013; 381:744-751.
12. Ruggenenti P, Remuzzi G: Idiopathic membranous nephropathy: back to the future? Lancet 2013; 381:706-708.
13. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, et al: A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989; 320:8-13.
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical Practice E6(R1). http://wwwichorg/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guidelinepdf (June 10, 1996) (accessed on August 1, 2014).
15. Chapter 7: ldiopathic membranous nephrop-Athy. Kidney Int Suppl (2011) 2012; 2:186-197.
16. van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF: Long-term outcomes in idiopath-ic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol 2014; 25:150-158.
17. Remuzzi A, Schieppati A, Battaglia C, Re-muzzi G: Angiotensin-converting enzyme inhibition ameliorates the defect in glomerular size selectivity in hyponatremic hypertensive syndrome. Am J Kidney Dis 1989; 14:170-177.
18. 2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11-21.
19. Debiec H, Ronco P: Immunopathogenesis of membranous nephropathy: an update. Semin Immunopathol 2014; 36:381-397.
20. Pescovitz MD: Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006; 6:859-866.
21. Remuzzi G, Chiurchiu C, Abbate M, Bruse-gan V, Bontempelli M, Ruggenenti P: Ritux-imab for idiopathic membranous nephropa-thy. Lancet 2002; 360:923-924.
22. Ruggenenti P, Chiurchiu C, Brusegan V, Ab-bate M, Perna A, Filippi C, et al: Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003; 14:1851-1857.
23. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH: Ritux-imab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009; 4:734-744.
24. Fervenza FC, Abraham RS, Erickson SB, Iraz-Abal MV, Eirin A, Specks U, et al: Rituximab therapy in idiopathic membranous nephrop-Athy: a 2-year study. Clin J Am Soc Nephrol 2010; 5:2188-2198.
25. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, et al: Rituximab treatment of idiopathic membranous ne-phropathy. Kidney Int 2008; 73:117-125.
26. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, et al: Rituximab in id-iopathic membranous nephropathy. J Am Soc Nephrol 2012; 23:1416-1425.
27. 2R autoan-tibodies and response to rituximab treatment in membranous nephropathy. J Am Soc Nephrol 2011; 22:1543-1550.
28. Makker SP, Kanalas JJ: Course of transplanted Heymann nephritis kidney in normal host. Implications for mechanism of proteinuria in membranous glomerulonephropathy. J Immunol 1989; 142:3406-3410.
29. Cravedi P, Sghirlanzoni MC, Marasa M, Salerno A, Remuzzi G, Ruggenenti P: Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol 2011; 33:461-468.
30. Segarra A, Praga M, Ramos N, Polanco N, Cargol I, Gutierrez-Solis E, et al: Successful treatment of membranous glomerulonephri-tis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009; 4:1083-1088.
31. Ruggenenti P, Cravedi P, Sghirlanzoni MC, Gagliardini E, Conti S, Gaspari F, et al: Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 2008; 3:1652-1659.
32. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al: Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:960-968.
33. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al: Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67: 1541-1544.
34. Merrill JT, Neuwelt CM, Wallace DJ, Shana-han JC, Latinis KM, Oates JC, et al: Efficacy and safety of rituximab in moderately-to-se-verely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233.
35. Stone JH, Merkel PA, Spiera R, Seo P, Lang-ford CA, Hoffman GS, et al: Rituximab versus cyclophosphamide for ANCA-Associated vas-culitis. N Engl J Med 2010; 363:221-232.
36. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al: Rituximab versus cyclophosphamide in ANCA-Associated renal vasculitis. N Engl J Med 2010; 363:211-220.
37. Carson KR, Evens AM, Richey EA, Haber-mann TM, Focosi D, Seymour JF, et al: Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834-4840.
38. Sellier-Leclerc AL, Belli E, Guerin V, Dor-fmuller P, Deschenes G: Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 2013; 28:1875-1879.
39. Delbue S, Ferraresso M, Elia F, Belingheri M, Carloni C, Signorini L, et al: Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab. J Med Virol 2012; 84:1464-1470.
40. Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al: Rituximab for childhood-onset, complicated, frequently relapsing ne-phrotic syndrome or steroid-dependent ne-phrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014, Epub ahead of print.
41. Ruggenenti P, Ruggiero B, Cravedi P, Vivar-elli M, Massella L, Marasa M, et al: Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 2014; 25:850-863.
42. Gea-Banacloche JC: Rituximab-Associated infections. Semin Hematol 2010; 47:187-198.
43. Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G, Kibbler CC: Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-Analysis. BMC Med 2011; 9:36.
44. Tan CS, Koralnik IJ: Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9:425-437.
45. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al: Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
46. van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF: Cancer risk after cyclophospha-mide treatment in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2014; 9: 1066-1073.
47. Feehally J: Targeted therapies: Is there a role for rituximab in nephrotic syndrome? Nat Rev Nephrol 2014; 10:245-247.
48. Kaufman GP, Aksamit AJ, Klein CJ, Yi ES, Delone DR, Litzow MR: Progressive multifo-cal leukoencephalopathy: a rare infectious complication following allogeneic hemato-poietic cell transplantation (HCT). Eur J Hae-matol 2014; 92:83-87.
49. Tavazzi E, Ferrante P, Khalili K: Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Micro-biol Infect 2011; 17:1776-1780.
50. Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al: Rituximab-Associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68:1156-1164.
51. Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, et al: A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet 2012; 51:119-135.
52. Ruggenenti P, Cravedi P, Remuzzi G: Ritux-imab for membranous nephropathy and immune disease: less might be enough. Nat Clin Pract Nephrol 2009; 5:76-77.
53. Gabardi S, Martin ST, Roberts KL, Grafals M: Induction immunosuppressive therapies in renal transplantation. Am J Health Syst Pharm 2011; 68:211-218.
54. Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, et al: Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009; 24:3717-3723.
55. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G: Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007; 2:932-937.
56. Jain P, O'Brien S: Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opin Biol Ther 2013; 13:169-182.
57. Basu B: Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med 2014; 370: 1268-1270.
58. Zhang B: Ofatumumab. MAbs 2009; 1: 326-331.
59. Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, et al: Safety and efficacy of ofatumumab in relapsing-remit-ting multiple sclerosis: a phase 2 study. Neurology 2014; 82:573-581.
60. Glassock RJ: The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum? Am J Kidney Dis 2004; 44:562-566.
61. Marasà M, Cravedi P, Ruggiero B, Ruggenen-ti P: Refractory focal segmental glomerulo-sclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab. BMJ Case Rep 2014;2014.